Continuous temperature tracking helps manage infection risk after CAR T-cell therapy

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

Don Dizon to join Tufts as system chief of hematology-oncology

Don S. Dizon will join Tufts Medicine in June 2025 as the system chief of hematology-oncology for the cancer service line. He will be proposed as the Jane F. Desforges endowed Professor in Hematology-Oncology at Tufts University School of Medicine.

April 04, 2025

Vol.51 No.13

Drugs & Targets

FDA approves durvalumab for muscle invasive bladder cancer

FDA approved AstraZeneca’s durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.

April 04, 2025

Vol.51 No.13

Capitol Hill

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.

March 28, 2025

Vol.51 No.12

By Claire Marie Porter and Jacquelyn Cobb

Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease.

March 28, 2025

Vol.51 No.12

By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie

Continuous temperature tracking helps manage infection risk after CAR T-cell therapy

YOU MAY BE INTERESTED IN

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Don Dizon to join Tufts as system chief of hematology-oncology

FDA approves durvalumab for muscle invasive bladder cancer

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

Renew today!

Subscriber content

Never miss an issue!

Login

Continuous temperature tracking helps manage infection risk after CAR T-cell therapy

YOU MAY BE INTERESTED IN

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Don Dizon to join Tufts as system chief of hematology-oncology

FDA approves durvalumab for muscle invasive bladder cancer

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunityWeill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

Never miss an issue!

Login

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration